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People are exposed to cadmium—a widespread
nephrotoxic pollutant—via food and tobacco
smoking. The ﬁrst sign of renal effects is tubu-
lar damage, characterized by increased urinary
excretion of low-molecular-weight proteins or
intracellular tubular enzymes. More important,
in succession to the tubular effects, Cd may
affect glomerular function (Åkesson et al.
2005; Bernard et al. 1992; Friberg 1950; Järup
et al. 1995; Nogawa 1984; World Health
Organization 1992). To protect people from
Cd-induced health effects, it is crucial to deter-
mine the critical exposure, that is, the concen-
tration of urinary Cd (U-Cd) below which the
probability of adverse health effects is low.
Attempts to estimate this limit for tubular
effects have so far displayed large variations in
critical U-Cd levels (1–10 μg U-Cd/g creati-
nine) (Buchet et al. 1980, 1990; Hong et al.
2004; Järup et al. 2000; Jin et al. 2004;
Lauwerys et al. 1979).
The benchmark dose (BMD) method is
increasingly used in the health risk assessment
of environmental contaminants [Crump 1984;
Filipsson et al. 2003; U.S. Environmental
Protection Agency (EPA) 1995]. Only in a few
cases has the BMD method been used for peo-
ple environmentally exposed to Cd (Hong
et al. 2004; Jin et al. 2004; Uno et al. 2005).
The BMD can be deﬁned as the exposure that
corresponds to a certain change in response
compared with the background. The lower
95% conﬁdence bound of the BMD (BMDL)
has been suggested to replace the no observed
adverse effect level (NOAEL) (Crump 1984;
U.S. EPA 1995). One major advantage of the
BMD/BMDL approach is that it uses the
whole dose–response curve (U.S. EPA 1995).
Thus, the BMD/BMDL is based on more
information than the NOAEL. By using a so-
called hybrid approach, the concept of risk can
be used for a continuous outcome (effect vari-
able). In that way, the limitations associated
with categorization of data can be avoided
(Crump 1995; Gaylor and Slikker 1990;
Kodell and West 1993; Ragland 1992).
Our aim in the present study was to deter-
mine the BMDs of U-Cd for Cd-induced
tubular and glomerular effects in an environ-
mentally exposed population, using the hybrid
approach. To evaluate the unique feature of the
hybrid approach, the obtained BMDs/BMDLs
were compared with the critical concentrations
obtained by the traditionally used procedures.
Materials and Methods
Study population and measurement. Within
the population-based Women’s Health in the
Lund Area (WHILA) study (Lidfeldt et al.
2001), conducted in an area with no particu-
lar industrial emission, we assessed health
effects of Cd in 820 women 53–64 years of
age (Åkesson et al. 2005). Subjects with renal
cancer and lithium treatment were excluded
(n = 4). In addition, because of effect modiﬁ-
cation (Åkesson et al. 2005), insulin-treated
subjects with diabetes were excluded from
calculation of the BMD for tubular (n = 14)
but not glomerular effects.
According to a questionnaire, 45% of the
included women had ever smoked (ever-
smokers). In addition, nonsteroidal anti-
inﬂammatory drugs (NSAIDs) were regularly
used by 6% of the women.
We used U-Cd as the measure of long-term
Cd exposure, urinary N-acetyl-β-D-glu-
cosaminidase (NAG) and human complex-
forming protein (protein HC) as markers of
tubular effects, and estimated glomerular ﬁl-
tration rate (GFR) based on cystatin C in
serum (estimated GFR = 77.24 × cystatin
C–1.2623) (Åkesson et al. 2005; Larsson et al.
2004) as a marker of glomerular effect
(Table 1). Urinary analytes were adjusted to a
speciﬁc gravity of 1.015 g/mL, because creati-
nine may not adjust for all dilution-related
variation of U-Cd (Suwazono et al. 2005).
However, because creatinine adjustment is
more commonly used, these values are given
for comparison. The ethics committee at
Lund University approved the WHILA study,
and oral informed consent was obtained from
each participant.
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OBJECTIVES: Our goal in this study was to explore the use of a hybrid approach to calculate bench-
mark doses (BMDs) and their 95% lower conﬁdence bounds (BMDLs) for renal effects of cadmium
in a population with low environmental exposure. 
METHODS: Morning urine and blood samples were collected from 820 Swedish women
53–64 years of age. We measured urinary cadmium (U-Cd) and tubular effect markers [N-acetyl-
β-D-glucosaminidase (NAG) and human complex-forming protein (protein HC)] in 790 women
and estimated glomerular filtration rate (GFR; based on serum cystatin C) in 700 women. Age,
body mass index, use of nonsteroidal anti-inﬂammatory drugs, and blood lead levels were used as
covariates for estimated GFR. BMDs/BMDLs corresponding to an additional risk (benchmark
response) of 5 or 10% were calculated (the background risk at zero exposure was set to 5%). The
results were compared with the estimated critical concentrations obtained by applying logistic
models used in previous studies on the present data. 
RESULTS: For both NAG and protein HC, the BMDs (BMDLs) of U-Cd were 0.5–1.1 (0.4–0.8) µg/L
(adjusted for speciﬁc gravity of 1.015 g/mL) and 0.6–1.1 (0.5–0.8) µg/g creatinine. For estimated
GFR, the BMDs (BMDLs) were 0.8–1.3 (0.5–0.9) µg/L adjusted for speciﬁc gravity and 1.1–1.8
(0.7–1.2) µg/g creatinine. 
CONCLUSION: The obtained benchmark doses of U-Cd were lower than the critical concentrations
previously reported. The critical dose level for glomerular effects was only slightly higher than that
for tubular effects. We suggest that the hybrid approach is more appropriate for estimation of the
critical U-Cd concentration, because the choice of cutoff values in logistic models largely inﬂuenced
the obtained critical U-Cd. 
KEY WORDS: benchmark dose, continuous data, environmental exposure, human, renal glomerular
dysfunction, renal tubular dysfunction, risk assessment, urinary cadmium. Environ Health Perspect
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lihood approach to ﬁt the dose–response curve
to the data (Crump 1995). For normally dis-
tributed data with constant variance, the log-
likelihood function, log L, is given by
where n is the number of subjects, di is the
dose for ith individual, σ2 is the variance,
μ(di) is the dose–response model for the
mean response, and yi is the response in the
ith individual. To obtain a symmetrical distri-
bution, data on NAG and protein HC were
log-transformed. Data on estimated GFR did
not have to be log-transformed. The model
for the mean response, μ(di), was assumed to
be linear:
μ(di) = β0 + β1 × di. [1]
We found signiﬁcant covariates only for esti-
mated GFR (Åkesson et al. 2005). Age, body
mass index, use of NSAIDs, and blood lead
levels (Åkesson et al. 2005) were included in
the model to control for possible confounding
of estimated GFR; NAG and protein HC dis-
played no such associations. Smoking (pack-
years) was not associated with any of the
kidney effect markers.
Calculation of BMDs. BMDs were calcu-
lated using a hybrid approach, which allows for
calculation of risk for continuous data without
dichotomizing the outcome (Crump 2002;
Gaylor and Slikker 1990; Sand et al. 2004).
The benchmark response (BMR), correspond-
ing to the BMD, was deﬁned as an additional
prespecified increase in the probability of
adverse response. For positive associations
between exposure (U-Cd) and effects (NAG
and protein HC), the effect level associated
with a certain BMR equals
μ(BMD) = μ(0) + σ{Φ–1[1–P(0)] 
– Φ–1[1–P(0)–BMR]},
where Φ–1 is the inverse of the standard nor-
mal cumulative distribution function and
P(0) is the cutoff level for adverse response
deﬁned in terms of a speciﬁed tail proportion
of a “hypothetical” control distribution (at
U-Cd = 0), equivalent to the background
probability of adverse response. The cutoff, c,
for the effect markers is given by
c = μ(0) + σ × Φ–1[1–P(0)].
The BMD is obtained by combining the
equation for μ(BMD) with that for the dose–
response (Equation 1):
[2]
For negative associations between exposure
and effects (β1 < 0), such as that for the asso-
ciation between Cd and estimated GFR, cal-
culations were performed in a similar way,
substituting the absolute value of β1 into
Equation 2 (Sand et al. 2003).
The BMDL was calculated using the pro-
file likelihood method (Crump 1995;
Filipsson et al. 2003). BMDs/BMDLs with
the P(0) = 5% and BMR = 5 or 10% were
calculated for all renal effect markers as repre-
sentative threshold levels. To describe how
the BMD/BMDL depends on the BMR and
P(0), data on NAG adjusted for speciﬁc grav-
ity were used as an example. We calculated
BMD/BMDL for three different BMRs (5,
10, or 20%) with varying P(0) (1–20%).
Comparisons with previously used proce-
dures. To compare the hybrid approach with
the previously used procedures, in which the
outcome is dichotomized, we applied the pro-
cedures used in the Cadmibel study (Buchet
et al. 1990) and the OSteoporosis, CAdmium
as a Risk Factor (OSCAR) study (Järup et al.
2000) on our data. In the Cadmibel study, the
relationship between renal adverse response
and U-Cd was investigated in a Belgian popu-
lation (Buchet et al. 1990). The authors
derived the cutoffs as the 95th percentile of
the renal tubular markers in a part of the study
population that was considered to be free from
kidney disease. The U-Cd levels at which the
probability of having an adverse response was
10% were estimated using a logistic model
after exclusion of individuals with diabetes and
regular use of NSAIDs. In the OSCAR study
(Järup et al. 2000), the adverse response of
protein HC in relation to U-Cd was investi-
gated in a Swedish population. The adverse
response was defined as urinary protein HC
above the 95th percentile (5.3 mg/g creati-
nine; 0.6 mg/mmol creatinine in women)
from another Swedish reference population
(Tencer et al. 1996). The U-Cd level at 15%
probability of an adverse response was then
estimated using parameters obtained by logis-
tic regression model in the OSCAR study.
We fitted our data to a logistic model.
The probability of adverse response at the
dose di of U-Cd is given by
[3]
where α is the log odds of adverse response at
the U-Cd = 0, and β is the slope for dose–log
odds relationship. Then, di is given by
[4]
The background probabilities and the U-Cd
levels at the 10% (Cadmibel) or 15%
(OSCAR) probability of adverse response
were estimated by Equations 3 and 4 and
compared with corresponding background
probability and U-Cd levels using the hybrid
approach.
Software. We used SPSS (version 12.0.1;
SPSS Inc., Chicago, IL, USA) and Microsoft
Excel (Microsoft Corp., Redmond, WA,
USA) for analyses. These results were veriﬁed
to be identical to the results by MATLAB
(version 7.0; MathWorks, Inc., Novi, MI,
USA) used in our previous studies (Sand et al.
2003, 2004).
Results
We found significant associations between
U-Cd, on the one hand, and NAG, protein
HC (both positive associations), and esti-
mated GFR (negative association), on the
other, based on the maximum likelihood
model (data not shown).
Table 2 shows the BMDs and BMDLs of
U-Cd using a cutoff, P(0), of 5% and a BMR
of 5 or 10% for the renal effect markers. For
the tubular effects (both NAG and protein
HC), the BMDLs of U-Cd were 0.4–0.8 μg/L,
corresponding to 0.5–0.8 μg/g creatinine. For
the glomerular effects (estimated GFR), the
BMDLs of U-Cd were 0.5–0.9 μg/L, corre-
sponding to 0.7–1.2 μg/g creatinine. We
obtained essentially the same BMD/BMDL if
we used cystatin C instead of estimated GFR.
We evaluated the effect of the cutoff value
[P(0)] and the response criteria (BMR) on the
BMDs/BMDLs. As shown in Figure 1, a
larger BMR and a smaller P(0) yield larger
BMD/BMDLs.
As shown in Figure 2A, the cutoff con-
centrations of NAG and protein HC obtained
by our hybrid approach modeling were lower
than those obtained by employing the proce-
dure used in the Cadmibel study in our study.
The opposite was observed for the OSCAR
procedure. In Figure 2B, the cutoffs from
Figure 2A are presented in terms of different
background probabilities of adverse response
[P(0)]. By using the predeﬁned cutoff values
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Table 1. Exposure and effect markers. 
Effect marker No. Mean ± SD
U-Cd
µg/L 790 0.61 ± 0.36
µg/g creatinine 0.76 ± 0.42
NAG
U/L 790 1.42 ± 1.09
U/g creatinine 1.78 ± 1.43
Protein HC
mg/L 790 3.05 ± 2.38
mg/g creatinine 3.92 ± 3.19
Serum cystatin C (mg/L) 700 0.82 ± 0.13
Estimated GFR (mL/min) 700 102.2 ± 18.9of the Cadmibel and OSCAR studies, we
obtained a lower and a higher P(0), respec-
tively (Figure 2B). When we compared the
critical concentration of U-Cd obtained by
the hybrid approach, the U-Cd levels were
lower than those obtained by applying the
Cadmibel procedure to our data. The oppo-
site was observed for the OSCAR procedure
(Figure 2C).
Discussion
To our knowledge, this is the ﬁrst estimation
of BMDs of Cd-induced renal effects using the
recently developed hybrid approach. The criti-
cal concentration was estimated for both tubu-
lar and glomerular effects in a population of
upper middle-age women living in an area in
southern Sweden without particular industrial
Cd emission. Generally, the critical concentra-
tions obtained by the hybrid method approach
were lower than those previously reported.
The present method has several methodo-
logic advantages. First, the BMDs/BMDLs
were calculated based on a continuous out-
come. Calculations of BMD/BMDL for con-
tinuous outcomes using the hybrid approach
has been developed during the last few years
(Crump 1995; Sand et al. 2004). The advan-
tage with the hybrid approach is that the cate-
gorization of subjects with respect to the
outcome variables can be avoided. Accordingly,
the statistical validity and efficiency of the
BMD is higher using the hybrid approach,
compared with methods involving dichotomi-
zation of a continuous outcome (Crump 2002;
West and Kodell 1999).
Second, we deﬁned the cutoff for adverse
effects as the 95th percentile, obtained by the
model at no Cd exposure (U-Cd = 0) in the
population under study, rather than as the
95th percentile of the effect marker in an
apparently low-exposed “reference” popula-
tion, with little information on the overall
comparability. Further, by estimating the cut-
off for adverse response by the model at zero
Cd exposure, any impact of the exposure level
in a reference group will be minimized. The
obtained critical U-Cd levels then corresponds
to an adverse response of 10% (5% additional
probability of adverse response; BMR = 5%)
or 15% (10% additional probability of adverse
response; BMR = 10%).
Third, we were able to avoid categoriza-
tion of the exposure variable. Except for the
fact that the number categories and the dose
interval for each category chosen may strongly
affect the result, categorization will decrease
the detection power (Royston et al. 2000).
Furthermore, we further improved the
method by using a multivariate linear regres-
sion model instead of a univariate model
(Hong et al. 2004; Jin et al. 2004; Uno et al.
2005) to enable the adjustment of BMD/
BMDL for potential confounders.
The BMDs for U-Cd obtained in the pre-
sent study were generally lower than the previ-
ously reported critical levels. For instance, the
lowest observed effect levels based on the same
data (Åkesson et al. 2005) were on average
10% higher than the present BMDs. In the
Cadmibel study (Buchet et al. 1990), the
U-Cd level corresponding to the 10% proba-
bility of adverse response was 1.9 μg/24 hr
(equivalent to about 2 μg/g creatinine) for cal-
ciuria and 2.7 μg/24 hr (roughly equivalent to
3 μg/g creatinine) for NAG. However, in the
OSCAR study (Järup et al. 2000), the U-Cd
Suwazono et al.
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Table 2. BMDs with their lower bounds (BMDL) corresponding to 5 and 10% additional risk (BMR) calcu-
lated using the hybrid approach. 
U-Cd BMD (BMDL)
Effect marker Cutoffa 5% BMR 10% BMR
NAG 
U/L 3.0 0.53 (0.41 µg/L)b 0.89 (0.69 µg/L)b
U/g creatinine 3.6 0.64 (0.50 µg/g creatinine) 1.08 (0.83 µg/g creatinine)
Protein HC 
mg/L 5.5 0.63 (0.47 µg/L)b 1.05 (0.78 µg/L)b
mg/g creatinine 6.8 0.63 (0.49 µg/g creatinine) 1.05 (0.81 µg/g creatinine)
Estimated GFR 
mL/min 82.6 0.80 (0.55 µg/L)b 1.34 (0.92 µg/L)b
mL/min 78.5 1.08 (0.70 µg/g creatinine) 1.80 (1.18 µg/g creatinine)
aCutoff values were deﬁned as 95th percentile of effect markers on the “hypothetical” control distrubution at U-Cd = 0.
bU-Cd was adjusted to mean speciﬁc gravity of 1.015.
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Figure 1. BMDs with BMDLs for U-Cd based on the tubular marker NAG (U/L) in relation to different cutoff
levels [P(0)] and BMRs. Both markers were adjusted to a speciﬁc gravity of 1.015 g/mL.
Figure 2. Cutoff values for the tubular markers (A),
corresponding background probabilities of adverse
response (B), and U-Cd at predetermined probabili-
ties of adverse response (C) by applying previously
used procedures and hybrid approach modeling to
our data. The values presented for the hybrid
approach correspond to the BMDs shown in Table 2.
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mg/g creatininelevel corresponding to 15% probability of
adverse response was 1.0 μg/g creatinine, simi-
lar to that obtained in the present study.
Further, the BMDLs obtained in the present
study were clearly lower than the BMDLs of
4–12 μg Cd/g creatinine (5% additional prob-
ability) obtained for various kidney effect
markers (NAG and isoform B), β2-micro-
globulin (β2-MG), retinol-binding protein,
and urinary albumin in China (Jin et al. 2004),
and slightly lower than the 0.9–1.2 μg Cd/g
creatinine (10% additional probability) (Hong
et al. 2004) obtained in another Chinese popu-
lation that was coexposed to arsenic. The pres-
ent BMDLs were, however, very similar to that
obtained in Japanese women 40–59 years of
age in a Cd-nonpolluted area. The BMDLs
(5% additional probability) for the kidney
effects (total protein, β2-MG, and NAG) were
0.6–1.8 μg/g creatinine (Uno et al. 2005). The
corresponding results for men were lower:
0.3–0.6 μg/g creatinine.
All of these other studies defined the
adverse response (cutoff) as the 95th percentile
in a reference population assumed to be non-
exposed (Hong et al. 2004; Järup et al. 2000;
Jin et al. 2004) or in a part of the study popu-
lation considered free from kidney disease
(Buchet et al. 1990; Uno et al. 2005). The
study subjects were then categorized (dichoto-
mous) as to the outcome. Obviously, a more
Cd-exposed reference group (Jin et al. 2002)
showed a considerably higher critical concen-
tration (Jin et al. 2004), emphasizing the need
for a better standardized method to obtain the
threshold for adverse response. In addition, all
the previous studies on U-Cd and BMD
(Hong et al. 2004; Jin et al. 2004; Uno et al.
2005) categorized the exposure into strata
(Benchmark Dose Software; U.S. EPA,
Washington, DC, USA). We consider the pre-
sent continuous approach of calculating the
BMD/BMDL more accurate and more effi-
cient in using the information.
When we applied previously used methods
to our data, the procedure used in the
Cadmibel study for deﬁning the cutoff resulted
in a background probability of < 5%, whereas
the procedure used in the OSCAR study
resulted in a background probability of > 5%.
The main reason for the higher P(0) in the lat-
ter study was that the reference population
was, on average, 20 years younger than the
study population. As illustrated in Equation 4
for the logistic regression, a low background
probability of adverse response P(0) yields a
larger [1 – P(0)]/P(0), which may yield a
larger critical U-Cd level (for a constant β).
Considered together, this shows that the cut-
off value has a strong effect on the estimated
critical level. Thus, the choice of reference
population for determination of the cutoff for
adverse effects (95th percentile) may have
large impact on the critical concentrations.
The advantage of the hybrid approach is that
it allows for estimation of the cutoff at zero
exposure in the population under study.
Although, compared with other methods,
the hybrid approach seemed to be better in
terms of the obtained critical concentration, it
is still, as for the logistic model, inﬂuenced by
the actual value of the background probability
of adverse response, P(0). On the other hand,
by using the hybrid approach, it is always pos-
sible to set a defined P(0), which allows for
interpopulation comparison of critical concen-
trations under the same conditions. This is
important because a lower P(0) leads to larger
BMD/BMDL, as shown in Figure 1. The rea-
son for this relates to the characteristics of the
normal distribution. The absolute distance
between two points on the distribution axis
that bracket, for example, a 5% probability
(i.e., a BMR = 5%) becomes higher in the
extreme tail region compared with in a more
central part of the distribution. Thus, the lower
P(0) becomes, the greater the distance between
the two points corresponding to P(0) and P(0)
+ BMR, which translates to a higher dose
(BMD) being required to produce the desired
change in probability (BMR). Furthermore,
the impact of P(0) on BMD was more pro-
nounced at lower than at higher values of P(0).
To our knowledge, such importance of back-
ground probability has not previously been
evaluated in detail for either the hybrid
approach or the logistic model.
In several previous studies, a P(0) of 5%
has been used as a standard for the hybrid
approach (Budtz-Jørgensen et al. 2000; Crump
et al. 2000; Jacobson et al. 2002; Murata et al.
2002, 2004), in accordance with the usual def-
inition of clinical reference intervals. The
adopted BMR levels in the present study are in
line with those used in other recent epidemio-
logic studies: 5% (Budtz-Jørgensen et al. 2000;
Murata et al. 2002, 2004) or 10% (Budtz-
Jørgensen et al. 2000; Crump et al. 2000).
Obviously, other P(0) values and BMRs can be
chosen, depending on the severity of the effects
(Jacobson et al. 2002).
The population-based design and the
rather high participation rate advocate gener-
alization of the results to other female popula-
tions in the same age interval. However, we
cannot exclude gender difference in BMDLs
for kidney effects (Uno et al. 2005).
In conclusion, the present BMDLs for
tubular effects, using a cutoff P(0) of 5%, were
0.4 μg/L (0.5 μg/g creatinine) at a BMR of
5% and 0.7 μg/L (0.8 μg/g creatinine) using a
BMR of 10%. The corresponding BMDLs for
the glomerular effect were 0.5 μg/L (0.7 μg/g
creatinine) and 0.9 μg/L (1.2 μg/g creatinine)
for BMRs of 5 and 10%, respectively. This
critical U-Cd level for glomerular effects was
lower and closer to the critical levels for tubu-
lar effects than expected from previous studies.
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